Payment overview · 2025
General Payments
$1,016.83
61 reported records · 19 companies
Healthcare provider profile · identity verified
Rekha Kesavan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LAWRENCEVILLE, GA · NPI 1497908560
Verified facts
What the public records show
CMS Open Payments records show Rekha Kesavan, M.D. received $1,016.83 in general payments during 2025 across 61 reported records.
Novo Nordisk Inc accounted for 22.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Rybelsus, Shingrix.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $223.88 | 22.0% | 16 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $181.64 | 17.9% | 13 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $103.16 | 10.2% | 6 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $72.57 | 7.1% | 3 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $61.40 | 6.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $53.95 | 5.3% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $51.79 | 5.1% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.87 | 3.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.50 | 3.5% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $29.10 | 2.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $25.55 | 2.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.38 | 2.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $18.41 | 1.8% | 1 | 2025 |
| bioMerieux Inc | Unresolved — no canonical attribution shown | $18.00 | 1.8% | 1 | 2025 |
| Vital Connect, Inc | Unresolved — no canonical attribution shown | $17.58 | 1.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.23 | 1.7% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $16.17 | 1.6% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.83 | 1.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.82 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,016.83 | 61 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $133.47 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $106.82 | 8 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $103.16 | 6 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $74.82 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $72.57 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $68.10 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $67.09 | 5 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $61.40 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $51.79 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $39.75 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $38.87 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $37.64 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $35.50 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $35.50 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $33.21 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $29.10 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $25.55 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.38 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $18.41 | 1 | 2025 |
Source payment records
|
|||||
| VITALPATCH RTM Normalized: vitalpatch rtm |
Device | Vital Connect, Inc | $17.58 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 89 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 20 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 93 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 192 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 86 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 20 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
93 | 37 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
20 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
192 | 47 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
86 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
89 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 632 | 249 |
| Levothyroxine Sodium | Levothyroxine Sodium | 572 | 158 |
| Amlodipine Besylate | Amlodipine Besylate | 509 | 190 |
| Metformin Hcl | Metformin Hcl | 376 | 128 |
| Losartan Potassium | Losartan Potassium | 280 | 108 |
| Lisinopril | Lisinopril | 233 | 88 |
| Ozempic | Semaglutide | 192 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 181 | 75 |
| Gabapentin | Gabapentin | 177 | 62 |
| Omeprazole | Omeprazole | 151 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 144 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 135 | 48 |
| Trazodone Hcl | Trazodone Hcl | 132 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 128 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 125 | 41 |
| Carvedilol | Carvedilol | 114 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 113 | 36 |
| Mounjaro | Tirzepatide | 111 | 23 |
| Simvastatin | Simvastatin | 100 | 37 |
| Sertraline Hcl | Sertraline Hcl | 98 | 39 |
| Jardiance | Empagliflozin | 93 | 37 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 91 | 76 |
| Zolpidem Tartrate | Zolpidem Tartrate | 91 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 90 | 30 |
| Eliquis | Apixaban | 89 | 24 |
| Rybelsus | Semaglutide | 86 | 32 |
| Alprazolam | Alprazolam | 85 | 29 |
| Famotidine | Famotidine | 85 | 38 |
| Montelukast Sodium | Montelukast Sodium | 77 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 71 | 39 |
| Nifedipine Er | Nifedipine | 69 | 31 |
| Potassium Chloride | Potassium Chloride | 65 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 64 | 29 |
| Allopurinol | Allopurinol | 63 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 20 |
| Azithromycin | Azithromycin | 62 | 54 |
| Bupropion Xl | Bupropion Hcl | 61 | 18 |
| Fenofibrate | Fenofibrate | 61 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 27 |
| Clonazepam | Clonazepam | 55 | 11 |
| Clonidine Hcl | Clonidine Hcl | 54 | suppressed |
| Furosemide | Furosemide | 53 | 19 |
| Glimepiride | Glimepiride | 53 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 27 |
| Ezetimibe | Ezetimibe | 51 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 16 |
| Glipizide | Glipizide | 50 | 17 |
| Lovastatin | Lovastatin | 49 | 18 |
| Atenolol | Atenolol | 48 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 47 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 40 |
| Januvia | Sitagliptin Phosphate | 44 | 14 |
| Fluconazole | Fluconazole | 41 | 30 |
| Metformin Hcl Er | Metformin Hcl | 39 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 38 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 36 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | 18 |
| Tramadol Hcl | Tramadol Hcl | 35 | 15 |
| Buspirone Hcl | Buspirone Hcl | 34 | 13 |
| Donepezil Hcl | Donepezil Hcl | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 24 |
| Ondansetron Odt | Ondansetron | 31 | 14 |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Tradjenta | Linagliptin | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Mirtazapine | Mirtazapine | 30 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 30 | 11 |
| Finasteride | Finasteride | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | suppressed |
| Estradiol | Estradiol | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Meloxicam | Meloxicam | 23 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Belsomra | Suvorexant | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 20 |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 15 |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 20 | 15 |
| Sucralfate | Sucralfate | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 17 |
| Methylphenidate Hcl | Methylphenidate Hcl | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,016.83 · 61 records | Novo Nordisk Inc | ACCRUFER, AIRSUPRA, AREXVY, CONTRAVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, Fluad, Flucelvax, JARDIANCE, KRYSTEXXA, Kerendia, Korlym, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, SHINGRIX, VITALPATCH RTM, Veozah, WaveWriter Alpha Prime 16, Wegovy, XIFAXAN | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error